Aktienanalyse zu Cingulate Inc (CING)CINGCingulate Inc

Cingulate Inc. is a biopharmaceutical company. The Company offers Precision Timed Release (PTR), which is a drug delivery platform technology to build and advance a pipeline of pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. It focuses on the treatment of attention deficit/hyperactivity disorder (ADHD) and anxiety. Its PTR platform incorporates an erosion barrier layer (EBL) designed to allow for the release of drug substances at specific, pre-defined time intervals. It develops stimulant medications which include CTx-1301 (dexmethylphenidate) and CTx-1302 (dextroamphetamine) for the treatment of ADHD across all three patient segments: children (aged 6 -12), adolescents (aged 13-17), and adults (aged 18+). It also develops CTx-2103 (buspirone), for the treatment of anxiety. It operates in the Healthcare sector (PHARMACEUTICAL PREPARATIONS industry).

Cingulate Inc is a good buy right now, trading at $5.03 with a 52-week high of $11.89, indicating significant upside potential. The stock has a positive RSI of 52.18, suggesting it is neither overbought nor oversold, which is favorable for entry. Additionally, the company is expected to resubmit its ADHD drug application, which could be a catalyst for price appreciation. However, there is a risk of continued losses, with a projected EPS of -0.48 for the next earnings date.